Human NARP mitochondrial mutation metabolism corrected with alpha-ketoglutarate/aspartate: a potential new therapy.
OBJECTIVE
To verify whether enhanced substrate-level phosphorylation increases viability and adenosine 5'-triphosphate (ATP) content of cells with neuropathy, ataxia, and retinitis pigmentosa/maternally inherited Leigh syndrome (NARP/MILS) mitochondrial DNA mutations and ATP synthase dysfunction.


METHODS
We used cell lines "poisoned" with oligomycin, the specific inhibitor of ATP synthase, and "natural" models, including transmitochondrial human cell lines (cybrids) harboring 2 different pathogenic mutations associated with the NARP/MILS phenotypes.


METHODS
Cell survival, morphology, and ATP content.


RESULTS
When normal human fibroblasts cultured in glucose-free medium were forced to increase energy consumption by exposure to the ionophore gramicidin or were energy challenged by oligomycin inhibition, their survival at 72 hours was 5%, but this increased to 70% when the medium was supplemented with alpha-ketoglutarate/aspartate to boost mitochondrial substrate-level phosphorylation. Homoplasmic cybrids harboring the 8993T-->G NARP mutation were also protected from death (75% vs 15% survival at 72 hours) by the supplemented medium and their ATP content was similar to controls.


CONCLUSIONS
These results show that ATP synthase-deficient cells can be rescued by increasing mitochondrial substrate-level phosphorylation and suggest potential dietary or pharmacological therapeutic approaches based on the supplementation of alpha-ketoglutarate/aspartate to patients with impaired ATP synthase activity.
Sgarbi
Gianluca
G
Dipartimento di Biochimica "G. Moruzzi", Università di Bologna, Bologna, Italy.
Casalena
Gabriella A
GA
Baracca
Alessandra
A
Lenaz
Giorgio
G
DiMauro
Salvatore
S
Solaini
Giancarlo
G
D000255:Adenosine Triphosphate / Q000378:metabolism*; D000891:Anti-Infective Agents, Local / Q000494:pharmacology; D001224:Aspartic Acid / Q000494:pharmacology*; D002097:C-Reactive Protein / Q000235:genetics*; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects* / Q000235:genetics*; D004272:DNA, Mitochondrial / Q000235:genetics*; D004734:Energy Metabolism / Q000187:drug effects* / Q000235:genetics*; D006096:Gramicidin / Q000494:pharmacology; D006801:Humans; D007656:Ketoglutaric Acids / Q000494:pharmacology*; D007888:Leigh Disease / Q000235:genetics; D008928:Mitochondria / Q000187:drug effects* / Q000235:genetics*; D025261:Mitochondrial Proton-Translocating ATPases / Q000037:antagonists & inhibitors* / Q000235:genetics*; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000235:genetics*; D009840:Oligomycins / Q000494:pharmacology*; D010085:Oxidative Phosphorylation / Q000187:drug effects; D012174:Retinitis Pigmentosa / Q000235:genetics; D013132:Spinocerebellar Degenerations / Q000235:genetics; D000099153:Pentraxins
D000255:Adenosine Triphosphate; D000891:Anti-Infective Agents, Local; D001224:Aspartic Acid; D002097:C-Reactive Protein; D004272:DNA, Mitochondrial; D006096:Gramicidin; D007656:Ketoglutaric Acids; D025261:Mitochondrial Proton-Translocating ATPases; D009419:Nerve Tissue Proteins; D009840:Oligomycins; D000099153:Pentraxins